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Abstract 
 
 
 
Purpose: To analyze the clinical, pharmacological and economical aspects of the cutaneous adverse 
drug reactions (ADRs) reported at Civil Hospital, Ahmedabad, India. 
Methods: A prospective observational study over a period of one and half years (November 2006 to 
April 2008) was undertaken. Semi-spontaneous reporting along with a review of case record forms were 
used. The reports were analyzed for clinical pattern, causal drug groups, causality (WHO-UMC criteria), 
severity (Hartwig and Siegel scale) and preventability (modified Schumock and Thornton criteria). The 
cost of ADRs was calculated on the basis of hospital expenditure per patient and the amount spent by 
patients themselves.  
Results: Out of 143 reports, chemotherapeutic agents (39 %) were the most commonly suspected 
drugs followed by unknown medicines (29 %). Most of the ADRs were designated as possible or 
probable (69 %) and moderately severe (96.5 %) in nature. However, 14 – 16 % were definitely 
preventable. Cost incurred by the hospital was Indian national rupees (INR) 374,255, i.e.,USD 8241. 
While average cost incurred by outpatients was INR 99 (USD 2.18) and that of hospitalized patients was 
INR 264 (USD 5.81). 
Conclusion: A large number of cutaneous ADRs are due to unknown medicines. This calls for strict 
drug control mechanisms, patient education regarding self-medication and maintenance of prescription 
records. The cost associated with ADRs is high. ADR monitoring is essential to reduce patient suffering 
as well as  to achieve the substantial savings in health care cost. 
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INTRODUCTION 
 
Drugs can cure, suppress or prevent a 
disease and are usually beneficial to humans. 
However, they can also produce 
undesirable/harmful effects, which are known 
as adverse drug reactions (ADRs). They 
account for about 5 % of all hospital 
admissions in UK [1]. Skin is one of the major 
target organs for ADRs. Cutaneous adverse 
drug reactions manifest as skin rashes and/or 
eruptions. The incidence of cutaneous ADRs 
among inpatients in developed countries 
ranges from 1 - 3% whereas in developing 
countries such as India it is 2-5 % [2]. It was 
estimated that 5 to 9 % of all hospital costs 
are related to ADRs [3]. Thus, ADRs are a 
significant economic burden, in addition to a 
frequent cause for the cessation of otherwise 
effective drug therapy in patients [4].  
 
This study aimed to analyze the clinico-
pharmacological characteristics and cost 
analysis of cutaneous ADRs reported at Civil 
Hospital, Ahmedabad, India, a tertiary care 
teaching hospital. 
 
PATIENTS AND METHODS 
 
A prospective observational study was 
conducted over a period of one and half year 
(November 2006 to April 2008) at a tertiary 
care teaching hospital in western India with a 
bed capacity of 2040 and average occupancy 
rate of 61 %. The institutional ethics 
committee approved the study protocol. The 
study site was the Department of 
Dermatology. The dermatology outpatient 
department (OPD) operates daily from 9 am 
to 5 pm and there is a designated ward for 
serious patients requiring hospitalization. The 
investigators visited the outpatient clinic daily 
as well as the in-patient ward of the 
department from 9.00 am to 12.00 noon. A 
semi-spontaneous reporting method was 
used to document  the ADRs. All the patients 
with clinically suspected cutaneous ADRs 
either attending the OPD or admitted in the 
ward, and willing to participate in study were 
included. 
 
The suspected ADRs were assessed by the 
consultant dermatologist and the relevant 
details were filled up in a case record form 
(CRF) after structured interview of the 
patient. The hospitalized patients were 
followed up daily until discharge. The 
outpatients were not followed up. The data 
obtained were analysed for clinical 
presentation of ADRs and causal drug 
groups. Causality assessment was carried 
out using WHO-UMC scale [5]. The severity 
of ADRs was categorized as mild, moderate 
and severe using Hartwig and Siegel scale 
[6]. Preventability of the ADRs was evaluated 
using the criteria of Schumock and Thornton, 
as modified by Lau et al [7]. Cost of ADRs 
was calculated as the expenses incurred by 
the hospital and the amount spent on 
transportation, medicines and loss of daily 
wages by the patients. Average hospital 
expenditure per patient per day is INR 1445 
(USD 31.86). The data collected were 
compared with other similar studies using Chi 
square test. P < 0.05 was considered as 
statistically significant. 
 
RESULTS   
 
A total of 143 ADRs reported during the study 
period that met with the inclusion/exclusion 
criteria were included. Out of these, thirty-
seven were hospitalized and 106 were OPD 
cases. A detailed analysis of these reports is 
given as follows. 
 
1. Clinical profile 
 
One-third of the patients were within the age 
range of 16 to 30 years (33.5 %) and man to 
woman ratio was 1.3:1. Most of the ADRs 
(71.3 %) developed within a week of drug 
administration. A total of 172 drugs 
suspected to be the cause of the reported 
cutaneous ADRs are shown in Figure 1. 
 
Antimicrobials were the most commonly 
suspected drugs followed by unknown 
medicines, non-steroidal anti-inflammatory 
drugs (NSAIDs) and antiepileptics. In fifty 
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cases, the nature of suspected drug was not 
known because patients had them without 
label and prescription. Among antimicrobials, 
the most common drugs were co-trimoxazole 
(15 %) and fluroquinolones (15 %) while 
phenytoin (67 %) and carbamazepine (20 %) 
were the commonest antiepileptics. A large 
number of clinical presentations were 
observed including fixed drug eruptions 
(FDEs), maculopapular rashes, urticaria, 
Steven Johnson syndrome (S.J.syndrome) 
angioedema, erythema multiforme etc. FDEs 
(27.3 %) were the commonest presentation 
followed by maculopapular rashes (24.5 %). 
A significant number (10.5 %) of patients 
developed S.J.syndrome. Phenytoin (33 %) 
and nevirapine (27 % ) were responsible for 
more than 50 % cases of S.J.syndrome. 
 
Fig 1: Causal drug groups for cutaneous ADRs 
 
2. Causality assessment of ADRs 
 
In 63 ADRs (41.6%), the response to 
dechallenge was satisfactory (as the event 
abated or started abating after stoppage of 
drug). In the rest of the patients, however, 
either it was not attempted (due to 
therapeutic reasons) or could not be 
assessed (lack of follow-up). An accidental 
rechallenge occurred in three cases leading 
to recurrence and 3 patients died of S. J. 
syndrome. The WHO-UMC scale was used 
for causality assessment. “Possible” (46 %) 
was the most common causal category 
followed by probable (23 %). In 42 (29 %) of 
the cases, it was rated as unassessable 
because the nature of drug was unknown.  
3.  Preventability 
 
A majority of the ADRs were not preventable 
(57 and 79%  of total and serious ADRs, 
respectively). However, as Figs 2 and 3 
indicate, 14% of total and 16% of serious 
ADRs were preventable. 
 
Fig 2: Preventability of all ADRs 
 
 
Fig 3: Preventability of serious ADRs 
 
Preventability could not be assessed in 42 
ADR reports, as the medication names were 
not available. 
 
4. Severity assessment (Hartwing scale) 
 
Most of the ADRs were moderately severe 
(138/143 or 96.5 %) while three cases were 
severe in nature, though preventable. 
         
5. Cost of ADRs 
 
Average stay of patients with cutaneous 
ADRs in our study was 7 days (95 %CI, 5.4, 
8.7; range 2 to 28 days). Hence, the average 
cost incurred by the hospital for patients with 
cutaneous ADRs was INR 10,115 (USD 223). 
The cost of ADR to patient was calculated for 
both out- and in-patients. For each outpatient, 
it was INR 99, i.e, USD 2.18 (95 %CI, 80.6, 
117.4; range INR 15 - 503), while for 
hospitalized patients, it was INR 264 (USD 
5.82) (95 %CI, 204.4, 323.6; range INR 35 - 
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878). Some of the hospitalized patients 
purchased the medicines from private 
pharmacy outlets whenever the drugs were 
not available in the hospital pharmacy. 
 
DISCUSSION 
 
This prospective study carried out over a 
period of eighteen months at a tertiary care 
centre showed that cutaneous ADRs 
developed within seven days (71.3%) to one 
month (16.1%) of the drug administration. 
This emphasizes the need to observe 
patients closely in the initial period of 
treatment. Several such studies have been 
carried out in India and elsewhere [8-13]. 
Antimicrobials were the commonest offending 
agents (67, 4 %) followed by unknown 
(unidentified) medicines, NSAIDs and 
antiepileptics. Pudukadan et al [9]
 
and 
Puvailai et al [10]
 
have also found 
antimicrobials frequent causal drugs for 
cutaneous ADRs. This is not surprising since 
antimicrobials are a common item in most 
prescriptions written in India and elsewhere
 
[14]. .  
 
Surprisingly, unknown or unidentified 
medicines constituted the second most 
common offending group, causing 40 non-
serious and 2 serious cutaneous ADRs. The 
nature of these drugs remained unknown 
because either the patients brought the drugs 
in loose, unidentified packs or had consumed 
them as self-medication. A large number of 
cutaneous ADRs with over the counter 
(OTCs) or unknown drugs call for stricter 
drug control measures, patient education 
regarding self-medication and maintenance 
of patient or prescription records.   
 
In the present study, cutaneous ADRs 
presented commonly as fixed drug eruptions 
(FDEs) - 27.3%, maculopapular rashes 
(24.5%) and urticaria (15.4%). Our 
observations were similar to those of 
Pudukadan et al [9] (see Table 1).
  
 
Noel et al [15] and Fiszenson-Albala et al [13] 
reported a significantly (p < 0.05) lower 
proportion of FDEs. The probable explanation 
for this difference may be because of genetic, 
ethnic or environmental factors which need 
an in depth analysis of these studies or the 
prescribing pattern of antimicrobials. In our 
study, cotrimoxazole was commonly 
prescribed while penicillin was frequently 
prescribed in other studies. We also 
observed that 11 % of cutaneous ADRs were 
SJ syndrome and three of the patients died. 
The higher occurrence of SJ syndrome in our 
study may be because we are  a tertiary care 
hospital, and  seriously sick patients are 
referred to us from within the state and also 
from  neighboring areas.  
 
Most of the ADRs in our study were 
designated as possible or probable in WHO-
UMC scale (69 %). However, 29 % of the 
ADRs were unassessable due to the 
unknown nature of the drug.  
 
A majority of ADRs were categorized as 
moderately severe while three cases were 
severe in nature. Assessing the severity of 
ADRs is an essential component in pharmac- 
 
 
Table 1: Comparison of cutaneous ADRs (present study) with other similar studies  
 
Clinical 
presentation 
Our study 
 (%, n=143) 
Ghosh et al 
(Manipal, 
south India 
 (%, n=53 
Pudukadan et al 
(south India) 
 (%,  
n=90) 
Puvailai et al 
(Bangkok, 
Thailand) 
 (%, n=132) 
Fiszenson-
Albala et al 
(France) 
 (%, n=48) 
Maculopapular 
rash 
25 21 12 60* 57* 
Fixed drug 
eruptions 
27 4* 31 9* 0 * 
S. J. syndrome 11 2* 19 5 2* 
 
* Statistically different (p < 0.05) compared to our study 
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ovigilance studies as an ADR  may require  
intervention including the stoppage of the 
suspected drug(s) and even hospitalization in 
severe cases. We also found that 14 % of 
total and 16 % of serious ADRs could have 
been prevented, resulting in considerable 
resource saving and avoidance of patient 
suffering. The past history in all these cases 
was suggestive of ADRs. A proper evaluation 
and history-taking would have prevented 
these ADRs. This could also have been 
brought to the notice of the prescribers to 
prevent recurrence in future. 
 
Cost of ADRs incurred by the hospital for 37 
hospitalized patients was INR 374,255 (USD 
8241). In our study, average hospital 
expenditure per patient was INR 10,115. A 
similar study done at Mumbai showed a cost 
of INR 6197 (USD 150) per patient in the 
hospital [16]. The difference may be 
attributed to drug prices, wages, food and 
telephone bills, and type of patients included 
in the study. Higher average cost incurred by 
hospitalized patients was partly due to the 
purchase of medicines from private pharmacy 
as sometimes drugs are not available in the 
hospital pharmacy (where drugs are 
generally cheaper)and also as a result of loss 
of daily wages.  
 
Limitations of study 
 
Due to lack of follow-up and inadequate 
record-keeping, the total number of patients 
treated at Dermatology OPD could not be 
ascertained and hence the incidence rates 
cannot be computed from the collected data. 
Moreover, ADRs of recently introduced drugs 
could also not be generated. 
 
CONCLUSION 
 
The present study demonstrates that a large 
number of cutaneous ADRs can be 
prevented. ADR monitoring can reduce 
patient suffering and cost of treatment. 
Patients’ awareness regarding OTC drugs 
and self-medication should also be 
strengthened.  
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